Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD4360 · 1 trial · 4 indications
To investigate the safety and tolerability, and to determine the Maximum Tolerated Dose (MTD) and/or a Recommended Phase II Dose (R2PD) of AZD4360 in previously treated participants with advanced solid tumours, through the assessment of Dose Limiting Toxicities, Adverse Events and Severe Adverse Events.
| Arm | Type | Description |
|---|---|---|
| AZD4360 Monotherapy | EXPERIMENTAL | AZD4360 Monotherapy |
| Name | Type | Description |
|---|---|---|
| AZD4360 | DRUG | Antibody-Drug Conjugate targeting Claudin 18.2 (CLDN18.2) |
Inclusion Criteria: 1. Participant must be ≥ 18 at the time of signing the ICF. 2. Eastern cooperative oncology group performance status of 0-1 with no deterioration over the previous 2 weeks prior to baseline or day of first dosing. 3. Minimum life expectancy of 12 weeks in the opinion of the Inve...
Top 20 of 47 competitors
AZD4360 is an investigational small molecule being studied for the treatment of gastric cancer, as well as gastroesophageal junction cancer, biliary tract cancer, and pancreatic ductal adenocarcinoma. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
AZD4360 is being developed by AstraZeneca PLC, a biopharmaceutical company traded on the stock exchange under the ticker symbol AZN. The drug is currently in Phase 1 clinical trials for advanced solid tumors.
AZD4360 is in Phase 1 clinical development. It is an investigational drug being studied in a single active clinical trial for advanced solid tumors, including gastric cancer. The drug has not yet been approved and remains under clinical investigation.
AZD4360 is being studied in one clinical trial with the identifier NCT06921928, titled "Study for AZD4360 in Participants With Advanced Solid Tumours." This Phase 1 trial is active but not recruiting, with an enrollment of 31 participants across the United States, China, Germany, Japan, and the United Kingdom.
AZD4360 is not FDA approved. It is an investigational drug currently in Phase 1 clinical trials for advanced solid tumors, including gastric cancer. The drug is still in clinical development and has not received regulatory approval.